Stock Analiz

Acrivon Therapeutics, Inc. ACRV

Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026

$1.45Market cap $62M
Open the interactive analysis →

Acrivon Therapeutics, Inc. (ACRV) is a healthcare company listed in the US with a market value of about $62M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -42%.

About Acrivon Therapeutics

Acrivon Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 834% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-103.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-42.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal year20252024202320222021
Revenue—————
Net income-$78M-$81M-$60M-$31M-$16M
Free cash flow-$65M-$68M-$44M-$32M-$14M
EPS (diluted)$-2.02$-2.38$-2.74$-7.56$-9.32
Net margin—————
ROIC-73.0%-39.1%-42.1%-14.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Acrivon Therapeutics pay a dividend?

Not currently.

Is Acrivon Therapeutics a good stock to buy?

We do not give buy or sell advice. Acrivon Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.